- Home
- SONN vs RNXT Comparison
SONN vs RNXT Comparison
Compare SONN & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- RNXT
- Stock Information
- Founded
- SONN N/A
- RNXT 2012
- Country
- SONN United States
- RNXT United States
- Employees
- SONN N/A
- RNXT N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- SONN Health Care
- RNXT Health Care
- Exchange
- SONN Nasdaq
- RNXT Nasdaq
- Market Cap
- SONN 32.4M
- RNXT 35.2M
- IPO Year
- SONN N/A
- RNXT 2021
- Fundamental
- Price
- SONN $4.02
- RNXT $0.90
- Analyst Decision
- SONN Strong Buy
- RNXT Strong Buy
- Analyst Count
- SONN 1
- RNXT 2
- Target Price
- SONN $20.00
- RNXT $7.75
- AVG Volume (30 Days)
- SONN 773.9K
- RNXT 377.5K
- Earning Date
- SONN 12-16-2025
- RNXT 11-13-2025
- Dividend Yield
- SONN N/A
- RNXT N/A
- EPS Growth
- SONN N/A
- RNXT N/A
- EPS
- SONN N/A
- RNXT N/A
- Revenue
- SONN $1,000,000.00
- RNXT $928,000.00
- Revenue This Year
- SONN $5,376.22
- RNXT $2,895.35
- Revenue Next Year
- SONN N/A
- RNXT $313.04
- P/E Ratio
- SONN N/A
- RNXT N/A
- Revenue Growth
- SONN 1689.52
- RNXT N/A
- 52 Week Low
- SONN $1.08
- RNXT $0.70
- 52 Week High
- SONN $19.30
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- SONN 44.01
- RNXT 45.56
- Support Level
- SONN $3.95
- RNXT $0.78
- Resistance Level
- SONN $5.06
- RNXT $0.83
- Average True Range (ATR)
- SONN 0.87
- RNXT 0.08
- MACD
- SONN -0.08
- RNXT 0.00
- Stochastic Oscillator
- SONN 18.83
- RNXT 48.05
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.